Company Filing History:

8 out of 2,945

Merck Patent Gmbh

patents

3 out of 1,248

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

patents

Years Active: 1998-2012

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8247448 - Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes (2012-08-21),

2. 8063067 - Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof (2011-11-22),

3. 7820847 - Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes (2010-10-26),

4. 7737176 - Substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them (2010-06-15),

5. 7691628 - Use of Rev-erb family of receptors in screening (2010-04-06),

6. 7678831 - Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof (2010-03-16),

7. 7632846 - Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof (2009-12-15),

8. 7482484 - Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia (2009-01-27),

9. 7465752 - Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof (2008-12-16),

10. 6998254 - Use of ROR for receptors for screening substances useful for the treatment of atherosclerosis (2006-02-14),

11. RE38629 - Solid oral dosage form comprising a combination of metformin and glibenclamide (2004-10-19),

12. 6512009 - Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator (2003-01-28),

13. 6372790 - Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia (2002-04-16),

14. 6303146 - Solid oral dosage form comprising a combination of metformin and glibenclamide (2001-10-16),

15. 5834448 - Dosage form of hydroxocobalamin and its use in cyanide poisoning (1998-11-10),

Title: Yves Bonhomme: Innovator in Pharmaceutical Chemistry

Introduction

Yves Bonhomme is a notable inventor based in Charbonnières les Bains, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds aimed at treating various health conditions.

Latest Patents

Yves Bonhomme holds 15 patents to his name. His latest patents include innovative work on butenoic acid derivatives, which involve processes for their preparation, pharmaceutical compositions that include these compounds, and their applications in treating dyslipidaemia, atherosclerosis, and diabetes. Another significant patent focuses on hexenoic acid derivatives, detailing their preparation processes, therapeutic applications, and pharmaceutical compositions.

Career Highlights

Throughout his career, Yves Bonhomme has worked with prominent companies in the pharmaceutical industry, including Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His work has been instrumental in advancing pharmaceutical formulations and therapeutic strategies.

Collaborations

Yves has collaborated with esteemed colleagues such as Valérie Guyard-Dangremont and Francis Contard, contributing to a rich exchange of ideas and innovations in the field.

Conclusion

Yves Bonhomme's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key figure in the development of treatments for critical health issues. His work continues to influence the industry and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com